Hangzhou Tigermed Consulting (300347) - Total Liabilities
Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) has total liabilities worth CN¥4.10 Billion CNY (≈ $600.31 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Hangzhou Tigermed Consulting to assess how effectively this company generates cash.
Hangzhou Tigermed Consulting - Total Liabilities Trend (2009–2025)
This chart illustrates how Hangzhou Tigermed Consulting's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Hangzhou Tigermed Consulting to evaluate the company's liquid asset resilience ratio.
Hangzhou Tigermed Consulting Competitors by Total Liabilities
The table below lists competitors of Hangzhou Tigermed Consulting ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Commercial & Savings Bank Ltd
TW:5876
|
Taiwan | NT$2.15 Trillion |
|
Chord Energy Corp
NASDAQ:CHRD
|
USA | $5.02 Billion |
|
Grupo Financiero Galicia S.A.
BA:GGAL
|
Argentina | AR$34.90 Trillion |
|
Sulzer AG
SW:SUN
|
Switzerland | CHF3.36 Billion |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $569.82 Million |
|
Chemed Corp
NYSE:CHE
|
USA | $546.94 Million |
|
Bank Millennium S.A.
WAR:MIL
|
Poland | zł146.55 Billion |
|
Definity Financial Corp
TO:DFY
|
Canada | CA$5.31 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Hangzhou Tigermed Consulting's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Hangzhou Tigermed Consulting.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou Tigermed Consulting's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou Tigermed Consulting (2009–2025)
The table below shows the annual total liabilities of Hangzhou Tigermed Consulting from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.10 Billion ≈ $600.31 Million |
-10.94% |
| 2024-12-31 | CN¥4.61 Billion ≈ $674.08 Million |
-11.87% |
| 2023-12-31 | CN¥5.23 Billion ≈ $764.90 Million |
+9.69% |
| 2022-12-31 | CN¥4.77 Billion ≈ $697.34 Million |
+51.96% |
| 2021-12-31 | CN¥3.14 Billion ≈ $458.89 Million |
+90.34% |
| 2020-12-31 | CN¥1.65 Billion ≈ $241.09 Million |
-19.50% |
| 2019-12-31 | CN¥2.05 Billion ≈ $299.50 Million |
+45.59% |
| 2018-12-31 | CN¥1.41 Billion ≈ $205.72 Million |
+79.81% |
| 2017-12-31 | CN¥781.85 Million ≈ $114.41 Million |
+42.53% |
| 2016-12-31 | CN¥548.54 Million ≈ $80.27 Million |
+0.81% |
| 2015-12-31 | CN¥544.12 Million ≈ $79.62 Million |
+23.46% |
| 2014-12-31 | CN¥440.72 Million ≈ $64.49 Million |
+733.66% |
| 2013-12-31 | CN¥52.87 Million ≈ $7.74 Million |
+37.24% |
| 2012-12-31 | CN¥38.52 Million ≈ $5.64 Million |
-5.43% |
| 2011-12-31 | CN¥40.73 Million ≈ $5.96 Million |
+68.85% |
| 2010-12-31 | CN¥24.12 Million ≈ $3.53 Million |
+4.29% |
| 2009-12-31 | CN¥23.13 Million ≈ $3.38 Million |
-- |
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more